Table 10. Clinical associations of UC/IBDU patients with ankylosing spondilitis / sacroliitis.
| No Anky spond./Sacro | Anky spond./Sacro | All UC/IBDU pat. | pvalue | |
|---|---|---|---|---|
| Number of patients | 1375 (95.6) | 63 (4.4) | 1438 (100.0) | |
| Gender | ||||
| Male | 741 (53.9) | 32 (50.8) | 773 (53.8) | |
| Female | 634 (46.1) | 31 (49.2) | 665 (46.2) | 0.630 |
| Age at diagnosis [y] (median,IQR, range) | 31, 32–40, 3–83 | 31, 23–42, 12–66 | 321, 23–41, 3–83 | 0.644 |
| Age at latest follow-up [y] (median, IQR, range) | 46, 36–57, 17–89 | 47, 39–59, 22–79 | 46, 36–57, 17–89 | 0.256 |
|
Disease duration [y] (median, IQR, range) |
12, 7–19, 0–59 | 13, 9–18, 2–49 | 12, 7–19, 0–59 | 0.071 |
|
BMI at latest follow-up [kg/m2] (median, IQR, range) |
24, 22–27, 18–38 | 22, 19–27, 17–30 | 24, 22–27, 17–38 | 0.391 |
| Initial disease location | ||||
| Pancolitis | 517 (37.6) | 22 (34.9) | 539 (37.5) | |
| Left-sided colitis | 435 (31.6) | 27 (42.9) | 462 (32.1) | |
| Proctitis | 272 (19.8) | 11 (17.5) | 283 (19.7) | |
| Unclear/Unknown | 151 (11.0) | 3 (4.8) | 154 (10.7) | 0.205 |
| Last disease location | ||||
| Pancolitis | 476 (34.6) | 20 (31.8) | 496 (34.5) | |
| Left-sided colitis | 496 (36.1) | 26 (41.3) | 522 (36.3) | |
| Proctitis | 243 (17.7) | 12 (19.1) | 255 (17.7) | |
| Unclear/Unknown | 160 (11.6) | 5 (7.9) | 165 (11.5) | 0.746 |
| MTWAI at enrollment (median, IQR, range) | 2, 1–5, 0–19 | 4, 1–7, 0–15 | 2, 1–5, 0–19 | 0.010 |
| MTWAI at latest follow-up (median, IQR, range) | 2, 0–3, 0–18 | 3, 1–4, 0–18 | 2, 0–4, 0–18 | 0.059 |
| Smoking status at diagnosis | ||||
| Non-smoker | 1034 (75.2) | 48 (76.2) | 1082 (75.2) | |
| Smoker | 288 (21.0) | 14 (22.2) | 302 (21.0) | |
| Unknown | 53 (3.8) | 1 (1.6) | 54 (3.8) | 0.790 |
| Smoking status at latest follow-up | ||||
| Non-smoker | 1168 (85.0) | 51 (81.0) | 1219 (84.4) | |
| Smoker | 187 (13.6) | 12 (19.0) | 199 (13.8) | |
| Unknown | 20 (1.4) | 0 (0.0) | 20 (1.4) | 0.422 |
| IBD-related surgery | 149 (10.8) | 11 (17.5) | 160 (11.1) | 0.102 |
| Anemia | ||||
| During SIBDCS follow-up | 401 (31.3) | 16 (26.7) | 417 (31.1) | 0.451 |
| At latest follow-up | 128 (13.5) | 6 (13.6) | 134 (13.5) | 1.000 |
|
Vit. B12 level at latest follow-up [pmo]/l)
(median, IQR, range) |
285, 208–371, 41–1696 | 242, 201–324, 110–1476 | 279, 207–369, 41–1696 | 0.261 |
| Ever received Vit. B12 Suppl. | 235 (22.4) | 20 (35.1) | 255 (23.1) | 0.027 |
| Treatment history | ||||
| 5-ASA | 1302 (94.7) | 61 (96.8) | 1363 (94.8) | 0.456 |
| Antibiotics | 150 (10.9) | 8 (12.7) | 158 (11.0) | 0.657 |
| Steroids | 1088 (79.1) | 54 (85.7) | 1142 (79.4) | 0.206 |
| Immunomodulators | 836 (60.8) | 46 (73.0) | 882 (61.3) | 0.052 |
| Anti-TNF | 468 (34.0) | 33 (52.4) | 501 (34.8) | 0.003 |
| Calcineurin inhibitors | 131 (9.5) | 8 (12.7) | 139 (9.7) | 0.405 |
| Extraintestinal manifestations | ||||
| Arthritis/Arthalgia | 453 (32.96) | 45 (71.4) | 498 (38.5) | <0.001 |
| Uveitis/Iritis | 64 (4.7) | 16 (25.4) | 25 (1.7) | <0.001 |
| Pyoderma Gangrenosum | 21 (1.5) | 4 (6.3) | 51 (3.5) | 0.021 |
| Erythema Nodosum | 47 (3.4) | 6 (6.4) | 79 (5.5) | 0.279 |
| Aphtous/oral ulcers | 70 (5.1) | 9 (14.3) | 44 (3.1) | 0.002 |
| PSC | 58 (4.2) | 3 (4.8) | 61 (4.2) | 0.747 |
| any of the above | 550 (40.0) | 52 (82.5) | 602 (41.9) | <0.001 |
| Family history of IBD | ||||
| None | 1087 (79.1) | 51 (81.0) | 1138 (79.1) | |
| Yes | 141 (10.2) | 0 (14.3) | 150 (10.4) | |
| Unknown | 147 (10.7) | 3 (4.7) | 150 (10.4) | 0.210 |